Systemic lupus erythematosus
Conditions
Interventions
Aspirin group:Take 100mg of aspirin per day
Rivaroxaban group:Take 10mg of rivaroxaban per day
Sponsors
The Second Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Classified as SLE according to the 2019 EULAR/ACR classification criteria; (2) Age >= 18 years old; (3) aPLs were negative in two consecutive tests (with an interval of >= 12 weeks): Lupus anticoagulant negative; Anti-cardiolipin antibody IgG/IgM 2.0 µg/mL (FEU) (2000 ug/L) and no obvious acute trigger; SLE-VTE score >= 100 points.
Exclusion criteria
Exclusion criteria: (1) Active bleeding or high-risk of bleeding (platelet count 5 times ULN); (3) Severe renal insufficiency (eGFR 12 points or requiring high-dose hormones / strong immunosuppression initiation / escalation; (10) Participating in other interventional clinical trials simultaneously; (11) Refusing to sign the informed consent form; (12) Healthcare workers participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary embolism;Venous thrombosis (Deep Vein Thrombosis); | — |
Secondary
| Measure | Time frame |
|---|---|
| Arterial thrombosis event;Massive hemorrhage event (according to ISTH standards);All-cause mortality;Change in disease activity; | — |
Countries
China
Contacts
Public ContactQiming Liu
The Second Xiangya Hospital of Central South University
Outcome results
None listed